AMENDMENTS TO THE CLAIMS

1-19. (Cancelled)

20. (Previously presented) A percutaneous absorption preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]acetamide, isopropyl myristate, polyethylene glycol and lauric diethanolamide.

21-32. (Cancelled)

33. (Previously presented) A percutaneous absorption preparation comprising a compound having a melatonin receptor agonist activity, lauric diethanolamide and optionally one or more members selected from fatty acid esters and polyhydric alcohols, wherein the compound having a melatonin receptor agonist activity is a compound represented by the formula:



wherein, R^1 represents a C_{1-6} alkyl group;

R^2 represents a hydrogen atom;

R^3 represents a hydrogen atom or a C_{1-6} alkyl group;

X represents CHR^4, NR^4 or O in which R^4 represents a hydrogen atom;

Y represents C or CH;

——— ····· represents a single bond or a double bond;

ring A represents a 5- membered oxygen-containing heterocyclic ring;

ring B represents a benzene ring; and

m represents an integer of 1 to 4;

or a salt thereof, wherein the percutaneous absorption preparation is contained in a skin contact member comprising silicon dioxide.

34-46. (Cancelled)

47. (Previously presented) The percutaneous absorption preparation according to claim 33, wherein the compound is (S)-N-[2-(1, 6, 7, 8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide.

48-49. (Cancelled)